Načítá se...
Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice
Despite significant advances in the management of acute coronary syndrome (ACS) and long-term antiplatelet therapy after an ACS event, patients continue to be at risk of further cardiovascular events. There is evidence that recurrent events are at least partly attributed to the persistent activation...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4027919/ https://ncbi.nlm.nih.gov/pubmed/24868164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/VHRM.S59420 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|